Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates (Q40427856)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates |
scientific article |
Statements
1 reference
Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates (English)
1 reference
Theresa M Allen
1 reference
Davis R Mumbengegwi
1 reference
Gregory J R Charrois
1 reference
1 May 2005
1 reference
1 reference
11
1 reference
9
1 reference
3567-3573
1 reference
Identifiers
1 reference
1 reference